AGP Executive Report

Cancer Care in Focus: The EMA CHMP has issued a positive opinion for pembrolizumab (Keytruda) plus enfortumab vedotin (Padcev) as perioperative treatment for resectable muscle-invasive bladder cancer, including a subcutaneous option (Keytruda SC/QLEX), with a final EU decision expected in Q4 2026—relevant for patients in Liechtenstein as well. Short Bowel Syndrome Update: Zealand Pharma’s glepaglutide (Zeydovio) won a positive CHMP opinion for adults with short bowel syndrome, aiming to reduce reliance on parenteral support; the company positions it as a major advance after more than a decade. Local Health Policy Debate: Liechtenstein’s abortion law vote has sparked a political standoff, with Parliament approving a 12-week time-limit regime by a narrow margin while the hereditary prince signals he will seek to block it. Access to Care via Funding: Norway Grants negotiations have restarted for Hungary, with planned funding earmarked for areas including health care—Norway, Iceland and Liechtenstein are part of the donor framework. Medical Tech & IP: A Unified Patent Court injunction blocks MGI Tech from selling CycloneSEQ sequencing systems across several European markets, including Liechtenstein, after an Oxford Nanopore patent dispute.

Cancer Care in Focus: The EMA CHMP has issued a positive opinion for Merck’s KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) as perioperative treatment for adults with resectable muscle-invasive bladder cancer, covering neoadjuvant therapy before radical cystectomy and continued adjuvant treatment after surgery; the recommendation also includes the subcutaneous KEYTRUDA SC option, with a final EU decision expected in Q4 2026 and coverage for EU states plus Iceland, Liechtenstein and Norway. Short Bowel Syndrome Update: Zealand Pharma also received a positive CHMP opinion for Zeydovio (glepaglutide) for adults with short bowel syndrome, citing results where many patients reduced weekly parenteral support and some weaned off entirely after 24 weeks. Local Health Policy Tension: Liechtenstein’s Parliament voted 13–12 for a 12-week abortion time-limit regime, but Catholic Prince Alois says he will oppose it and intends to veto the citizen initiative. Research & Access: A Unified Patent Court injunction blocks MGI Tech from selling or supplying CycloneSEQ sequencing systems across several European markets, including Liechtenstein, after Oxford Nanopore alleged patent infringement. Funding for Health Systems: Hungary has restarted talks with Norway Grants, with plans that could direct major funding toward green development and areas including health care and institutional development.

Bladder Cancer Treatment Update: The EMA’s CHMP has issued a positive opinion for pembrolizumab (Keytruda) plus enfortumab vedotin (Padcev) as perioperative treatment for adults with resectable muscle-invasive bladder cancer, with the plan starting before surgery (neoadjuvant) and continuing after radical cystectomy (adjuvant); the recommendation also covers the subcutaneous pembrolizumab option (Keytruda SC/Keytruda QLEX), and the European Commission is expected to make a final decision in Q4 2026 for the EU plus Iceland, Liechtenstein, and Norway. Short Bowel Syndrome: Zealand Pharma also received a positive CHMP opinion for Zeydovio (glepaglutide), a long-acting GLP-2 analog, for adults with short bowel syndrome—reported results include many patients cutting weekly parenteral support and some weaning off entirely after 24 weeks. Local Health Policy Clash: Liechtenstein’s abortion debate is back in focus after Parliament voted 13–12 for a 12-week time-limit approach, while the hereditary prince has vowed to oppose and block the measure. Research & Access: A Unified Patent Court injunction has halted MGI Tech’s CycloneSEQ sequencing systems across multiple European markets, including Liechtenstein, after an IP dispute with Oxford Nanopore.

Cancer Care in Focus: The EMA’s CHMP has issued a positive opinion for pembrolizumab (Keytruda) plus enfortumab vedotin-ejfv (Padcev) as perioperative treatment for adults with resectable muscle-invasive bladder cancer (MIBC), to be given before radical cystectomy and continued after surgery; the review now goes to the European Commission for marketing authorization in the EU, Iceland, Liechtenstein and Norway, with a final decision expected in Q4 2026. Broader Eligibility: A related CHMP opinion also supports pembrolizumab (or pembrolizumab QLEX) plus Padcev for perioperative use across all resectable MIBC patients eligible for surgery, not just those who are cisplatin-ineligible. Short Bowel Treatment: Zealand Pharma received a positive CHMP opinion for Zeydovio™ (glepaglutide) for adults with short bowel syndrome, reporting that many patients reduced weekly parenteral support and some weaned off entirely after 24 weeks. Local Health Policy Debate: Liechtenstein’s Catholic hereditary prince says he will oppose the newly approved abortion bill after Parliament voted 13–12 for a 12-week time limit. Legal/Access Angle: A Unified Patent Court injunction blocks MGI Tech from selling or supplying CycloneSEQ sequencing systems across multiple markets including Liechtenstein, after an IP dispute with Oxford Nanopore.

Cancer Care Update: The EU’s CHMP has issued a positive opinion for Merck’s KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv)—with a QLEX option—for perioperative treatment of resectable muscle-invasive bladder cancer, potentially expanding use to all patients eligible for radical cystectomy; a final European Commission decision is expected in Q4 2026 and would apply to Liechtenstein. Short Bowel Syndrome: Zealand Pharma also received a positive CHMP opinion for Zeydovio (glepaglutide), aiming to reduce reliance on parenteral support in adults with short bowel syndrome. Local Health Policy: Liechtenstein’s abortion debate is back in focus after Parliament voted narrowly for a 12-week limit, while the hereditary prince signals he will oppose/veto the bill. Research & Access: A court order in a patent dispute blocks MGI Tech from selling certain CycloneSEQ sequencing systems across several European markets, including Liechtenstein.

Bladder Cancer Treatment Update: The EU medicines watchdog CHMP has issued a positive opinion for Merck’s KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) as perioperative therapy for adults with resectable muscle-invasive bladder cancer, including patients regardless of cisplatin eligibility; a final European Commission decision is expected in Q4 2026, and it would also apply to Liechtenstein, Iceland and Norway. Short Bowel Syndrome Breakthrough: Zealand Pharma also received a positive CHMP opinion for Zeydovio (glepaglutide) for adults with short bowel syndrome, with results reported as two thirds achieving at least a 20% reduction in weekly parenteral support volume after 24 weeks. Local Health Politics: Liechtenstein’s abortion debate remains in focus after Parliament voted 13–12 for a 12-week time-limit regime, while the hereditary prince has signaled he intends to block it. Cross-Border Care & Health Policy: A separate report notes German-speaking health ministers meeting to strengthen cross-border cooperation in Luxembourg, relevant for regional care coordination.

Short Bowel Syndrome Treatment: The EMA’s CHMP has issued a positive opinion for Zealand Pharma’s Zeydovio™ (glepaglutide), recommending marketing authorization for adults with short bowel syndrome—reported as the first major European advance in over a decade, with many patients reducing weekly parenteral support and some weaning off entirely after 24 weeks. Liechtenstein Abortion Politics: Liechtenstein’s Catholic hereditary prince Alois says he will defend unborn life and intends to oppose the abortion bill after Parliament voted 13–12 for a 12-week time-limit regime, setting up a constitutional showdown over whether the prince sanctions the law. Cross-Border Health & Care Tech: A Unified Patent Court injunction blocks MGI Tech from selling or supplying Oxford Nanopore’s CycloneSEQ sequencing systems across several European markets, including Liechtenstein, after claims of patent infringement. Health Policy Context: A week of debate around abortion in Catholic microstates continues, with Liechtenstein’s vote contrasted against Andorra’s plan to decriminalize abortion ahead of elections. Human Rights Watch: The UK and 37 OSCE states have called for the release of all political prisoners in Belarus, citing ongoing repression and politically motivated prosecutions.

Abortion Law Clash in Liechtenstein: Parliament narrowly voted 13–12 to legalize abortion up to 12 weeks, but Hereditary Prince Alois says he will veto the citizen initiative—setting up a constitutional showdown over whether the law can take effect. Cross-Border Health Tech: A Unified Patent Court injunction blocks MGI Tech from selling Oxford Nanopore’s CycloneSEQ sequencing systems across several European markets, including Liechtenstein, after an IP dispute. Regional Abortion Debate: Andorra and Liechtenstein are both Catholic microstates facing abortion reform—Andorra moves toward decriminalization, while Liechtenstein’s prince signals resistance. Pharma Tariff Uncertainty: With pharmaceutical tariffs due to start Sept. 29, businesses say guidance on exemptions and compliance is still unclear, raising concerns for drug access and investment. Education & Health Link: Luxembourg’s school year begins amid PISA worries, with inclusion reforms and new learning initiatives under scrutiny—an indirect pressure point for long-term student wellbeing.

Royal Health & Wellness Angle: Princess Charlene of Monaco returned to the palace with Prince Albert for the SENS network event, wearing a minimalist neutral dress with an asymmetrical sleeve cut—an easy reminder that comfort and confidence can share the same spotlight. Abortion Rights in Europe: Andorra and Liechtenstein are both wrestling with abortion policy under Catholic-influenced constitutional setups—Andorra moving toward decriminalization, while Liechtenstein’s first-12-weeks legalization faces resistance from the hereditary prince. Biotech & Access to Care: With pharmaceutical tariffs looming, industry groups say compliance rules and exemptions are still unclear, raising costs and threatening drug access. Patent & Tech for Medicine: A Unified Patent Court injunction blocks MGI Tech from selling CycloneSEQ sequencing systems across multiple markets including Liechtenstein, after Oxford Nanopore alleged patent infringement. Education & Teacher Support: Estonia opened the EDUHUB teacher center in Zhytomyr with €330,000 for renovations and training, focusing on better preschool education methods. Cross-Border Mobility: The US published ESTA entry guidance for citizens of 42 countries, listing required documents and steps for visa-free travel.

Abortion Policy Clash in Liechtenstein: Parliament has narrowly approved legal elective abortion in the first 12 weeks, but the hereditary prince has signaled he will block it, leaving the law not yet in force; the Church warns the country lacks balanced conditions, including access to local maternity care. Cross-Border Health Risk: A new “European Shamonda” virus is spreading among dairy cattle in France and has been reported in Germany, Switzerland, Liechtenstein and the Netherlands, with vets flagging higher risks for pregnant animals. Medical Tech & Access: A Unified Patent Court injunction stops MGI Tech from selling/supplying its CycloneSEQ sequencing systems across several European markets, including Liechtenstein, after Oxford Nanopore alleged patent infringement. Education & Health Link: Estonia opened the EDUHUB teacher training center in Zhytomyr, funded with €330,000, focusing on educator support and interactive learning tools. Policy Uncertainty for Pharma: Guidance on looming pharmaceutical tariffs remains unclear, raising concerns about costs, investment and patient access.

Liechtenstein Abortion Vote: Liechtenstein’s parliament backed an elective abortion proposal for the first 12 weeks (13–12), but it still won’t take effect because Hereditary Prince Alois has signaled he will veto it—sparking renewed debate over access to care, including concerns about women seeking inpatient obstetric services abroad. Animal Health Alert: France reports rapid spread of “European Shamonda” among dairy cattle, now in 22 departments after earlier cases in Germany, Switzerland, Liechtenstein and the Netherlands; vets warn the virus can be mild to moderate but poses serious risks for pregnant animals, including miscarriage and birth defects. Pharma Policy Uncertainty: With U.S. pharmaceutical tariffs due to start Sept. 29, industry groups say compliance guidance and exemptions are still unclear, raising costs and threatening drug access and investment in new treatments. Regional Health Context: A week of European coverage also flagged education pressures tied to health and wellbeing indirectly, as Luxembourg pupils return to school amid PISA concerns and inclusion debates.

Abortion Rights in Liechtenstein: Liechtenstein’s parliament backed an initiative to allow elective abortion in the first 12 weeks, but it won’t take effect yet because Hereditary Prince Alois has announced a veto; the proposal would also lift limits on doctors sharing information and shift costs to health insurance, while the Church warns the country lacks balance and that many women may seek inpatient care abroad. Animal Health Alert: France reports a rapid spread of “European Shamonda” among dairy cattle, now in 22 departments, with vets warning the virus can be mild to moderate but poses serious risks for pregnant animals, including miscarriage and birth defects. Cross-Border Health Policy: Health ministers from the “health quintet” (Germany, Austria, Switzerland, Liechtenstein, Luxembourg) met in Luxembourg to compare pension reforms, workplace prevention, and tackling neurodegenerative diseases. Local Health & Care Economy: A Luxembourg-focused recap highlights ongoing education concerns tied to health and wellbeing indirectly, as pupils return to school amid PISA worries and inclusion debates. Medical Innovation Watch: Implantica announced a Capital Markets Day in Stockholm on Sept. 9 to discuss its FDA-approved RefluxStop® and plans for the U.S. launch.

Pharma Policy Uncertainty: With new tariffs on patented pharmaceuticals and input materials set to start Sept. 29, industry groups say key compliance rules and exemptions are still unclear—raising costs, discouraging investment, and risking patient access to medicines. Liechtenstein Reproductive Health: Liechtenstein’s parliament backed an initiative to allow elective abortion in the first 12 weeks, but Hereditary Prince Alois is expected to veto it; the debate also highlights concerns about access to obstetric care and the country’s restrictive current law. Animal Health Alert: France reports rapid spread of “European Shamonda” among dairy cattle, with warnings that while severity may be mild to moderate, pregnant animals face serious risks including miscarriage and birth defects. Cross-Border Health Cooperation: Health ministers from the “health quintet” (Germany, Austria, Switzerland, Liechtenstein, Luxembourg) met in Luxembourg to discuss pension systems, workplace prevention, and neurodegenerative diseases. Workplace Prevention Focus: The same ministerial talks emphasized keeping people in employment longer by improving workplace conditions and prevention measures. Local Health Tech/Innovation: Implantica announced a Capital Markets Day in Stockholm to discuss its FDA-approved reflux device RefluxStop® and plans for a U.S. launch.

Pharmaceutical Tariffs Uncertainty: With patented drug and input tariffs due Sept. 29, biotech groups say key compliance rules and exemptions are still unclear—raising costs, discouraging investment, and risking patient access. Abortion Rights in Liechtenstein: Parliament narrowly backed a first-12-weeks elective abortion initiative, but Hereditary Prince Alois has signaled a veto; the proposal would also lift limits on abortion-related information and shift costs to health insurance. Animal Health Alert: France reports rapid spread of “European Shamonda” among dairy cattle, with cases now in multiple countries including Liechtenstein; vets warn of risks for pregnant animals, including miscarriage and birth defects. Cross-Border Health Cooperation: German-speaking health ministers met in Luxembourg to discuss modernizing pension systems, workplace prevention, and tackling neurodegenerative diseases. EV Battery Warranty Expansion: AVILOO’s battery warranty is now live across more European markets, including Liechtenstein, aiming to boost used-EV buyer confidence with standardized battery “state of health” coverage. Workforce & Health Systems: Research on international students in the region highlights net economic benefits—relevant to health and social services planning as populations and labor needs shift.

Animal Health Alert: France’s epidemiological surveillance reports rapid spread of “European Shamonda” among dairy cattle, now in 22 departments after earlier cases in Germany, Switzerland, Liechtenstein and the Netherlands; vets say it’s spread by midges and, while often mild-to-moderate, poses serious risks for pregnant animals, including miscarriage and birth defects. Liechtenstein Reproductive Health: Liechtenstein’s parliament narrowly backed a first-12-weeks elective abortion initiative, but Hereditary Prince Alois has pledged to veto; the proposal would also lift abortion-related information restrictions and shift costs to health insurance, while critics warn about “protection of life” and note many people currently travel abroad for care. Cross-Border Health Policy: German-speaking health ministers met in Luxembourg to discuss modernising pension systems, workplace prevention to help people stay employed longer, and tackling neurodegenerative diseases through stronger regional cooperation. Health & Wellness Business: Implantica announced its Capital Markets Day in Stockholm (Sept 9) focused on RefluxStop® after FDA approval, targeting the large U.S. acid reflux market. Workforce & Care: Dutch research from CPB suggests international students are a net economic plus over time, with a meaningful share of graduates staying to work.

Animal Health Alert: France reports rapid spread of “European Shamonda” among dairy cattle, now detected in 22 departments after earlier cases in Germany, Switzerland, Liechtenstein and the Netherlands; symptoms include fever, diarrhea, appetite loss and lower milk output, with vets warning of serious risks for pregnant animals (miscarriage or birth defects). Reproductive Rights in Liechtenstein: Liechtenstein’s parliament backed a proposal to allow elective abortion in the first 12 weeks, but Hereditary Prince Alois has pledged to veto it; the debate also highlights the country’s restrictive rules and the role of an information ban that pushes many people to seek care abroad. Regional Health Policy: German-speaking health ministers met in Luxembourg as part of the “health quintet” (Germany, Austria, Switzerland, Liechtenstein, Luxembourg), focusing on modernising pension systems, workplace prevention, and neurodegenerative diseases. Health Tech & Care Access: Implantica announced its Capital Markets Day in Stockholm (Sept 9) to discuss RefluxStop® after FDA approval, including plans for the U.S. launch for acid reflux treatment.